

INTRODUCTION .....	XVIII
STUDY GOALS AND OBJECTIVES.....	XVIII
REASONS FOR STUDY.....	XVIII
SCOPE OF STUDY.....	XVIII
METHODOLOGY AND INFORMATION SOURCES.....	XIX
ANALYST CREDENTIALS.....	XIX
RELATED BCC REPORTS .....	XIX
BCC ONLINE SERVICES.....	XX
INTERNET .....	XX
DISCLAIMER .....	XXI
 EXECUTIVE SUMMARY .....	 XXII
<i>SUMMARY TABLE GLOBAL AND U.S. TOTAL MARKET FOR CENTRAL NERVOUS</i>	
<i>SYSTEM PSYCHOTHERAPEUTIC DRUGS, REVENUES AT U.S.</i>	
<i>MANUFACTURERS' SALES LEVELS, THROUGH 2007 (\$ MILLIONS).....</i>	<i>XXIII</i>
<i>SUMMARY FIGURE GLOBAL AND U.S. MARKET FOR CENTRAL NERVOUS</i>	
<i>SYSTEM PSYCHOTHERAPEUTIC DRUGS, REVENUES AT U.S.</i>	
<i>MANUFACTURERS' SALES LEVELS, 2000-2007 (\$ MILLIONS).....</i>	<i>XXIII</i>
 INDUSTRY OVERVIEW.....	 1
HISTORICAL PERSPECTIVE OF THE MENTAL HEALTH	
INDUSTRY .....	1
HISTORICAL PERSPECTIVE (CONTINUED) .....	2
HISTORICAL PERSPECTIVE (CONTINUED) .....	3
HISTORICAL PERSPECTIVE (CONTINUED) .....	4
HISTORICAL PERSPECTIVE (CONTINUED) .....	5
HISTORICAL PERSPECTIVE (CONTINUED) .....	6
HISTORICAL PERSPECTIVE (CONTINUED) .....	7
HISTORICAL PERSPECTIVE (CONTINUED) .....	8
INTRODUCTION TO THE NERVOUS SYSTEM AND BRAIN .....	9
BLOOD-BRAIN BARRIER .....	10
MENTAL HEALTH DISORDERS.....	11
Alzheimer's Disease.....	11
<i>TABLE 1 MAJOR CAUSES OF PROGRESSIVE DEMENTIA (%).....</i>	<i>11</i>
Alzheimer's Disease (Continued) .....	12
Alzheimer's Disease (Continued) .....	13
Alzheimer's Disease (Continued) .....	14
Alzheimer's Disease (Continued) .....	15
<i>TABLE 2 PHARMACOLOGIC MANAGEMENT OF ALZHEIMER'S DISEASE .....</i>	<i>16</i>
Anxiety Disorders .....	16
Generalized Anxiety Disorder .....	17
Panic Disorder.....	17
Panic Disorder (Continued).....	18
Post-traumatic Stress Disorder .....	19
Specific and Social Phobias .....	20

<i>TABLE 3 CLINICAL NAMES FOR COMMON PHOBIAS</i> .....	20
Attention Deficit Hyperactivity Disorder .....	21
Bipolar Disorder .....	22
Bipolar I Disorder .....	22
Bipolar II Disorder .....	22
Cyclothymic Disorder.....	23
Borderline Personality Disorder .....	23
Borderline Personality Disorder (Continued).....	24
Depression.....	25
Depression (Continued) .....	26
Eating Disorders.....	27
Anorexia Nervosa.....	27
Bulimia Nervosa .....	28
Obsessive-Compulsive Disorder.....	29
Schizophrenia .....	30
Schizophrenia (Continued).....	31
Schizophrenia (Continued).....	32
Sleep Disorders .....	33
Insomnia.....	34
Narcolepsy.....	35
Restless Legs Syndrome .....	36
Parasomnia .....	36
arasomnia (Continued).....	37
Substance Abuse-related Disorders.....	38
Substance Abuse-related Disorders (Continued).....	39
Alcohol Abuse.....	40
Drug Abuse.....	41
DEMOGRAPHICS.....	41
<i>TABLE 4 ESTIMATED INCIDENCE/PREVALENCE OF CONDITIONS, 2000</i> <i>(THOUSANDS)</i> .....	42
PRESCRIBING TRENDS .....	42
PEDIATRIC AND ADOLESCENT USE .....	43
PRESCHOOLER USE .....	44
PHARMACEUTICAL TESTING IN CHILDREN .....	44
COST.....	45
Cost (Continued).....	46
REIMBURSEMENT ISSUES.....	47
Reimbursement Issues (Continued).....	48
LEGISLATIVE ACTIONS .....	49
Legislative Actions (Continued).....	50
ELDERLY IMPACT .....	51
Elderly Impact (Continued).....	52
Elderly Impact (Continued).....	53
Elderly Impact (Continued).....	54
Elderly Impact (Continued).....	55

Elderly Impact (Continued).....	56
PSYCHIATRIC PHARMACOGENETICS.....	57
PATENT ISSUES AND GENERIC PARTICIPATION .....	57
TABLE 5 PATENT EXPIRATION FOR SELECTED PRESCRIPTION	
PSYCHOTHERAPEUTICS 2002.....	58
COMPLIANCE ISSUES .....	59
Compliance Issues (Continued).....	60
Compliance Issues (Continued).....	61
Compliance Issues (Continued).....	62
INTERNET ADDICTION—FACT OR FICTION .....	63
GENETIC LINK TO MULTIPLE DISORDERS .....	64
PSYCHIATRIC DISEASES ON THE RISE.....	65
Psychiatric Diseases on the Rise (Continued).....	66
MENTAL HEALTH AGENDA SETTING—ANOTHER VIEW .....	67
Mental Health Agenda (Continued).....	68
Mental Health Agenda (Continued).....	69
Mental Health Agenda (Continued).....	70
HEALTHCARE REFORM .....	71
Healthcare Reform (Continued).....	72
PRESCRIPTION CENTRAL NERVOUS SYSTEM DEPRESSANTS	
AND ANTIANXIETY DRUGS .....	73
OVERVIEW .....	73
MARKETED PRODUCTS .....	74
Barbiturates.....	74
Benzodiazepines .....	74
Miscellaneous Central Nervous System Depressants and	
Antianxiety Drugs.....	75
MARKET SIZE AND FORECAST.....	76
TABLE 6 MARKET SIZE OF GLOBAL CENTRAL NERVOUS SYSTEM	
DEPRESSANTS AND ANTIANXIETY DRUGS BY REVENUES AT U.S.	
MANUFACTURERS' SALES LEVELS, THROUGH 2007 (\$ MILLIONS).....	77
FIGURE 1 MARKET SIZE OF GLOBAL CENTRAL NERVOUS SYSTEM	
DEPRESSANTS AND ANTIANXIETY DRUGS BY REVENUES AT U.S.	
MANUFACTURERS' SALES LEVELS, 2000-2007 (\$ MILLIONS).....	77
TABLE 7 MARKET SIZE OF U.S. CENTRAL NERVOUS SYSTEM DEPRESSANTS	
AND ANTIANXIETY DRUGS BY REVENUES AT U.S. MANUFACTURERS' SALES	
LEVELS, THROUGH 2007 (\$ MILLIONS).....	78
FIGURE 2 MARKET SIZE OF U.S. CENTRAL NERVOUS SYSTEM DEPRESSANTS	
AND ANTIANXIETY DRUGS BY REVENUES AT U.S. MANUFACTURERS' SALES	
LEVELS, 2000-2007 (\$ MILLIONS) .....	78
TABLE 8 GEOGRAPHICAL DISTRIBUTION OF GLOBAL CENTRAL NERVOUS	
SYSTEM DEPRESSANTS AND ANTIANXIETY DRUGS BY REVENUES AT U.S.	
MANUFACTURERS' SALES LEVELS, THROUGH 2007 (%).....	79
FIGURE 3 GEOGRAPHICAL DISTRIBUTION OF GLOBAL CENTRAL NERVOUS	
SYSTEM DEPRESSANTS AND ANTIANXIETY DRUGS BY REVENUES AT U.S.	
MANUFACTURERS' SALES LEVELS, 2000-2007 (%) .....	79
PRODUCTS IN THE PIPELINE.....	79

<i>TABLE 9 PRESCRIPTION CENTRAL NERVOUS SYSTEM DEPRESSANTS AND ANTIANXIETY DRUGS IN DEVELOPMENT 2002</i> .....	80
Products in the Pipeline (Continued) .....	81
COMPETITIVE ANALYSIS .....	82
<i>TABLE 10 GLOBAL CENTRAL NERVOUS SYSTEM DEPRESSANTS AND ANTIANXIETY DRUG MANUFACTURER MARKET SHARE BY REVENUES, 2002</i> .....	83
<i>FIGURE 4 CENTRAL NERVOUS SYSTEM DEPRESSANTS AND ANTIANXIETY DRUG MANUFACTURER PERCENTAGE MARKET SHARE BY REVENUES, 2002</i> .....	83
PRESCRIPTION CENTRAL NERVOUS SYSTEM	
ANTIDEPRESSANT DRUGS .....	84
OVERVIEW .....	84
MARKETED PRODUCTS .....	84
Monoamine Oxidase Inhibitors .....	84
Selective Serotonin Reuptake Inhibitors.....	85
Selective Serotonin Reuptake Inhibitors (Continued) .....	86
Tricyclic Antidepressants .....	87
Miscellaneous Antidepressants.....	87
Miscellaneous Antidepressants (Continued) .....	88
MARKET SIZE AND FORECAST.....	89
<i>TABLE 11 MARKET SIZE OF GLOBAL CENTRAL NERVOUS SYSTEM ANTIDEPRESSANT DRUGS BY REVENUES AT U.S. MANUFACTURERS' SALES LEVELS, THROUGH 2007 (\$ MILLIONS)</i> .....	89
<i>FIGURE 5 MARKET SIZE OF GLOBAL CENTRAL NERVOUS SYSTEM ANTIDEPRESSANT DRUGS BY REVENUES AT U.S. MANUFACTURERS' SALES LEVELS, 2000-2007 (\$ MILLIONS)</i> .....	90
<i>TABLE 12 MARKET SIZE OF U.S. CENTRAL NERVOUS SYSTEM ANTIDEPRESSANT DRUGS BY REVENUES AT U.S. MANUFACTURERS' SALES LEVELS, THROUGH 2007 (\$ MILLIONS)</i> .....	90
<i>FIGURE 6 MARKET SIZE OF U.S. CENTRAL NERVOUS SYSTEM ANTIDEPRESSANT DRUGS BY REVENUES AT U.S. MANUFACTURERS' SALES LEVELS, 2000-2007 (\$ MILLIONS)</i> .....	91
<i>TABLE 13 GEOGRAPHICAL DISTRIBUTION OF GLOBAL CENTRAL NERVOUS SYSTEM ANTIDEPRESSANT DRUGS BY REVENUES AT U.S. MANUFACTURERS' SALES LEVELS, THROUGH 2007 (%)</i> .....	91
<i>FIGURE 7 GEOGRAPHICAL DISTRIBUTION OF GLOBAL CENTRAL NERVOUS SYSTEM ANTIDEPRESSANT DRUGS BY REVENUES AT U.S. MANUFACTURERS' SALES LEVELS, 2000-2007 (%)</i> .....	92
PRODUCTS IN THE PIPELINE.....	92
<i>TABLE 14 PRESCRIPTION CENTRAL NERVOUS SYSTEM ANTIDEPRESSANT DRUGS IN DEVELOPMENT 2002</i> .....	93
Products in the Pipeline (Continued) .....	94
COMPETITIVE ANALYSIS .....	95
<i>TABLE 15 CENTRAL NERVOUS SYSTEM ANTIDEPRESSANT DRUG MANUFACTURER MARKET SHARE BY REVENUES, 2002</i> .....	96
<i>FIGURE 8 CENTRAL NERVOUS SYSTEM ANTIDEPRESSANT DRUG MANUFACTURER PERCENT MARKET SHARE BY REVENUES, 2002 (%)</i> .....	97
PRESCRIPTION CENTRAL NERVOUS SYSTEM ANTIMANIC DRUGS.....	97

OVERVIEW .....	97
MARKETED PRODUCTS .....	98
Lithium .....	98
Miscellaneous Antimanic Drugs .....	98
MARKET SIZE AND FORECAST.....	98
TABLE 16 MARKET SIZE OF GLOBAL CENTRAL NERVOUS SYSTEM ANTIMANIC DRUGS BY REVENUES AT U.S. MANUFACTURERS' SALES LEVELS, THROUGH 2007 (\$ MILLIONS).....	99
FIGURE 9 MARKET SIZE OF GLOBAL CENTRAL NERVOUS SYSTEM ANTIMANIC DRUGS BY REVENUES AT U.S. MANUFACTURERS' SALES LEVELS, 2000-2007 (\$ MILLIONS).....	99
TABLE 17 MARKET SIZE OF U.S. CENTRAL NERVOUS SYSTEM ANTIMANIC DRUGS BY REVENUES AT U.S. MANUFACTURERS' SALES LEVELS, THROUGH 2007 (\$ MILLIONS).....	100
FIGURE 10 MARKET SIZE OF U.S. CENTRAL NERVOUS SYSTEM ANTIMANIC DRUGS BY REVENUES AT U.S. MANUFACTURERS' SALES LEVELS, 2000-2007 (\$ MILLIONS).....	100
TABLE 18 GEOGRAPHICAL DISTRIBUTION OF GLOBAL CENTRAL NERVOUS SYSTEM ANTIMANIC DRUGS BY REVENUES AT U.S. MANUFACTURERS' SALES LEVELS, THROUGH 2007 (%).....	101
FIGURE 11 GEOGRAPHICAL DISTRIBUTION OF GLOBAL CENTRAL NERVOUS SYSTEM ANTIMANIC DRUGS BY REVENUES AT U.S. MANUFACTURERS' SALES LEVELS, 2000-2007 (%) .....	101
PRODUCTS IN THE PIPELINE.....	102
TABLE 19 PRESCRIPTION CENTRAL NERVOUS SYSTEM ANTIMANIC DRUGS IN DEVELOPMENT 2002.....	102
COMPETITIVE ANALYSIS .....	103
TABLE 20 CENTRAL NERVOUS SYSTEM ANTIMANIC DRUG MANUFACTURER MARKET SHARE BY REVENUES, 2002 .....	104
FIGURE 12 CENTRAL NERVOUS SYSTEM ANTIMANIC DRUG MANUFACTURER PERCENT MARKET SHARE BY REVENUES, 2002.....	104
PRESCRIPTION CENTRAL NERVOUS SYSTEM ANTIPSYCHOTIC DRUGS.....	105
OVERVIEW .....	105
MARKETED PRODUCTS .....	105
Phenothiazines and Combinations .....	105
Miscellaneous Antipsychotic Agents.....	106
MARKET SIZE AND FORECAST.....	107
TABLE 21 MARKET SIZE OF GLOBAL CENTRAL NERVOUS SYSTEM ANTIPSYCHOTIC DRUGS BY REVENUES AT U.S. MANUFACTURERS' SALES LEVELS, THROUGH 2007 (\$ MILLIONS).....	108
FIGURE 13 MARKET SIZE OF GLOBAL CENTRAL NERVOUS SYSTEM ANTIPSYCHOTIC DRUGS BY REVENUES AT U.S. MANUFACTURERS' SALES LEVELS, 2000-2007 (\$ MILLIONS) .....	108
TABLE 22 MARKET SIZE OF U.S. CENTRAL NERVOUS SYSTEM ANTIPSYCHOTIC DRUGS BY REVENUES AT U.S. MANUFACTURERS' SALES LEVELS, THROUGH 2007 (\$ MILLIONS).....	109
FIGURE 14 MARKET SIZE OF U.S. CENTRAL NERVOUS SYSTEM ANTIPSYCHOTIC DRUGS BY REVENUES AT U.S. MANUFACTURERS' SALES LEVELS, 2000-2007 (\$ MILLIONS) .....	109

TABLE 23 GEOGRAPHICAL DISTRIBUTION OF GLOBAL CENTRAL NERVOUS SYSTEM ANTIPSYCHOTIC DRUGS BY REVENUES AT U.S. MANUFACTURERS' SALES LEVELS, THROUGH 2007 (%).....	110
FIGURE 15 GEOGRAPHICAL DISTRIBUTION OF GLOBAL CENTRAL NERVOUS SYSTEM ANTIPSYCHOTIC DRUGS BY REVENUES AT U.S. MANUFACTURERS' SALES LEVELS, 2000-2007 (%) .....	110
PRODUCTS IN THE PIPELINE.....	111
TABLE 24 PRESCRIPTION CENTRAL NERVOUS SYSTEM ANTIPSYCHOTIC DRUGS IN DEVELOPMENT, 2002.....	111
COMPETITIVE ANALYSIS .....	112
TABLE 25 CENTRAL NERVOUS SYSTEM ANTIPSYCHOTIC DRUG MANUFACTURER MARKET SHARE BY REVENUES, 2002 .....	113
FIGURE 16 CENTRAL NERVOUS SYSTEM ANTIPSYCHOTIC DRUG MANUFACTURER PERCENT MARKET SHARE BY REVENUES, 2002.....	114
PRESCRIPTION CENTRAL NERVOUS SYSTEM STIMULANT DRUGS.....	114
OVERVIEW .....	114
MARKETED PRODUCTS .....	115
Amphetamines.....	115
Miscellaneous Central Nervous System Stimulants.....	116
MARKET SIZE AND FORECAST.....	116
TABLE 26 MARKET SIZE OF GLOBAL CENTRAL NERVOUS SYSTEM STIMULANT DRUGS BY REVENUES AT U.S. MANUFACTURERS' SALES LEVELS, THROUGH 2007 (\$ MILLIONS).....	117
FIGURE 17 MARKET SIZE OF GLOBAL CENTRAL NERVOUS SYSTEM STIMULANT DRUGS BY REVENUES AT U.S. MANUFACTURERS' SALES LEVELS, 2000-2007 (\$ MILLIONS) .....	117
TABLE 27 MARKET SIZE OF U.S. CENTRAL NERVOUS SYSTEM STIMULANT DRUGS BY REVENUES AT U.S. MANUFACTURERS' SALES LEVELS, THROUGH 2007 (\$ MILLIONS).....	118
FIGURE 18 MARKET SIZE OF U.S. CENTRAL NERVOUS SYSTEM STIMULANT DRUGS BY REVENUES AT U.S. MANUFACTURERS' SALES LEVELS, 2000-2007 (\$ MILLIONS).....	118
TABLE 28 GEOGRAPHICAL DISTRIBUTION OF GLOBAL CENTRAL NERVOUS SYSTEM STIMULANT DRUGS BY REVENUES AT U.S. MANUFACTURERS' SALES LEVELS, THROUGH 2007 (%).....	119
FIGURE 19 GEOGRAPHICAL DISTRIBUTION OF GLOBAL CENTRAL NERVOUS SYSTEM STIMULANT DRUGS BY REVENUES AT U.S. MANUFACTURERS' SALES LEVELS, 2000-2007 (%) .....	119
PRODUCTS IN THE PIPELINE.....	119
TABLE 29 PRESCRIPTION CENTRAL NERVOUS SYSTEM STIMULANT DRUGS IN DEVELOPMENT, 2002.....	120
COMPETITIVE ANALYSIS .....	120
TABLE 30 CENTRAL NERVOUS SYSTEM STIMULANT DRUG MANUFACTURER MARKET SHARE BY REVENUES, 2002 .....	121
FIGURE 20 CENTRAL NERVOUS SYSTEM STIMULANT DRUG MANUFACTURER PERCENT MARKET SHARE BY REVENUES, 2002 (%).....	122
PRESCRIPTION CENTRAL NERVOUS SYSTEM CHOLINESTERASE INHIBITOR AND MISCELLANEOUS ALZHEIMER TREATMENT DRUGS .....	122

OVERVIEW .....	122
MARKETED PRODUCTS .....	122
MARKET SIZE AND FORECAST.....	123
<i>TABLE 31 MARKET SIZE OF GLOBAL CENTRAL NERVOUS SYSTEM CHOLINESTERASE INHIBITOR AND MISCELLANEOUS ALZHEIMER TREATMENT DRUGS BY REVENUES AT U.S. MANUFACTURERS' SALES LEVELS, THROUGH 2007 (\$ MILLIONS).....</i>	<i>124</i>
<i>FIGURE 21 MARKET SIZE OF GLOBAL CENTRAL NERVOUS SYSTEM CHOLINESTERASE INHIBITOR AND MISCELLANEOUS ALZHEIMER TREATMENT DRUGS BY REVENUES AT U.S. MANUFACTURERS' SALES LEVELS, 2000-2007 (\$ MILLIONS) .....</i>	<i>124</i>
<i>TABLE 32 MARKET SIZE OF U.S. CENTRAL NERVOUS SYSTEM CHOLINESTERASE INHIBITOR AND MISCELLANEOUS ALZHEIMER TREATMENT DRUGS BY REVENUES AT U.S. MANUFACTURERS' SALES LEVELS, THROUGH 2007 (\$ MILLIONS).....</i>	<i>125</i>
<i>FIGURE 22 MARKET SIZE OF U.S. CENTRAL NERVOUS SYSTEM CHOLINESTERASE INHIBITOR AND MISCELLANEOUS ALZHEIMER TREATMENT DRUGS BY REVENUES AT U.S. MANUFACTURERS' SALES LEVELS, 2000-2007 (\$ MILLIONS) .....</i>	<i>125</i>
<i>TABLE 33 GEOGRAPHICAL DISTRIBUTION OF GLOBAL CENTRAL NERVOUS SYSTEM CHOLINESTERASE INHIBITOR AND MISCELLANEOUS ALZHEIMER'S DRUGS BY REVENUES AT U.S. MANUFACTURERS' SALES LEVELS, THROUGH 2007 (%) .....</i>	<i>126</i>
<i>FIGURE 23 GEOGRAPHICAL DISTRIBUTION OF GLOBAL CENTRAL NERVOUS SYSTEM CHOLINESTERASE INHIBITOR AND MISCELLANEOUS ALZHEIMER'S DRUGS BY REVENUES AT U.S. MANUFACTURERS' SALES LEVELS, 2000-2007 (%).....</i>	<i>126</i>
PRODUCTS IN THE PIPELINE.....	126
<i>TABLE 34 PRESCRIPTION CENTRAL NERVOUS SYSTEM CHOLINESTERASE INHIBITORS AND ALZHEIMER TREATMENT DRUGS IN DEVELOPMENT, 2002 .....</i>	<i>127</i>
<i>TABLE 34 (CONTINUED) .....</i>	<i>128</i>
COMPETITIVE ANALYSIS .....	129
<i>TABLE 35 CENTRAL NERVOUS SYSTEM CHOLINESTERASE INHIBITOR AND MISCELLANEOUS ALZHEIMER TREATMENT DRUG MANUFACTURER MARKET SHARE BY REVENUES, 2002 .....</i>	<i>130</i>
<i>FIGURE 24 CENTRAL NERVOUS SYSTEM CHOLINESTERASE INHIBITOR AND MISCELLANEOUS ALZHEIMER TREATMENT DRUG MANUFACTURER PERCENT MARKET SHARE BY REVENUES, 2002 (%).....</i>	<i>130</i>
PRESCRIPTION CENTRAL NERVOUS SYSTEM SUBSTANCE ABUSE TREATMENT DRUGS .....	131
OVERVIEW .....	131
MARKETED PRODUCTS .....	131
MARKET SIZE AND FORECAST.....	132
<i>TABLE 36 MARKET SIZE OF GLOBAL CENTRAL NERVOUS SYSTEM SUBSTANCE ABUSE TREATMENT DRUGS BY REVENUES AT U.S. MANUFACTURERS' SALES LEVELS, THROUGH 2007 (\$ MILLIONS).....</i>	<i>133</i>
<i>FIGURE 25 MARKET SIZE OF GLOBAL CENTRAL NERVOUS SYSTEM SUBSTANCE ABUSE TREATMENT DRUGS BY REVENUES AT U.S. MANUFACTURERS' SALES LEVELS, 2000-2007 (\$ MILLIONS).....</i>	<i>133</i>

TABLE 37 MARKET SIZE OF U.S. CENTRAL NERVOUS SYSTEM SUBSTANCE ABUSE TREATMENT DRUGS BY REVENUES AT U.S. MANUFACTURERS' SALES LEVELS, THROUGH 2007 (\$ MILLIONS).....	134
FIGURE 26 MARKET SIZE OF U.S. CENTRAL NERVOUS SYSTEM SUBSTANCE ABUSE TREATMENT DRUGS BY REVENUES AT U.S. MANUFACTURERS' SALES LEVELS, 2000-2007 (\$ MILLIONS).....	134
TABLE 38 GEOGRAPHICAL DISTRIBUTION OF GLOBAL CENTRAL NERVOUS SYSTEM SUBSTANCE ABUSE TREATMENT DRUGS BY REVENUES AT U.S. MANUFACTURERS' SALES LEVELS, THROUGH 2007 (%).....	135
FIGURE 27 GEOGRAPHICAL DISTRIBUTION OF GLOBAL CENTRAL NERVOUS SYSTEM SUBSTANCE ABUSE TREATMENT DRUGS BY REVENUES AT U.S. MANUFACTURERS' SALES LEVELS, 2000-2007 (%).....	135
PRODUCTS IN THE PIPELINE.....	135
TABLE 39 PRESCRIPTION CENTRAL NERVOUS SYSTEM SUBSTANCE ABUSE TREATMENT DRUGS IN DEVELOPMENT, 2002 .....	136
COMPETITIVE ANALYSIS .....	137
TABLE 40 CENTRAL NERVOUS SYSTEM SUBSTANCE ABUSE DRUG MANUFACTURER MARKET SHARE BY REVENUES, 2002 .....	137
FIGURE 28 CENTRAL NERVOUS SYSTEM SUBSTANCE ABUSE DRUG MANUFACTURER PERCENT MARKET SHARE BY REVENUES, 2002 (%).....	138
TOTAL MARKET SUMMARY .....	138
INDUSTRY STRUCTURE.....	138
GLOBAL MARKET FOR PSYCHOTHERAPEUTIC DRUGS .....	139
TABLE 41 GLOBAL MARKET FOR CENTRAL NERVOUS SYSTEM PSYCHOTHERAPEUTIC DRUGS, REVENUES AT U.S. MANUFACTURERS' SALES LEVELS, THROUGH 2007 (\$ MILLIONS).....	139
FIGURE 29 GLOBAL MARKET FOR CENTRAL NERVOUS SYSTEM PSYCHOTHERAPEUTIC DRUGS, REVENUES AT U.S. MANUFACTURERS' SALES LEVELS, 2000-2007 (\$ MILLIONS).....	140
GLOBAL MARKET PERCENTAGE BY PRODUCT TYPE.....	140
TABLE 42 GLOBAL MARKET PERCENT FOR CENTRAL NERVOUS SYSTEM PSYCHOTHERAPEUTIC DRUGS BY CATEGORY, 2002.....	141
U.S. MARKET FOR PSYCHOTHERAPEUTIC DRUGS .....	141
TABLE 43 U.S. MARKET FOR CENTRAL NERVOUS SYSTEM PSYCHOTHERAPEUTIC DRUGS, REVENUES AT U.S. MANUFACTURERS' SALES LEVELS, THROUGH 2007 (\$ MILLIONS).....	141
FIGURE 30 U.S. MARKET FOR CENTRAL NERVOUS SYSTEM PSYCHOTHERAPEUTIC DRUGS, REVENUES AT U.S. MANUFACTURERS' SALES LEVELS, 2000-2007 (\$ MILLIONS).....	142
U.S. MARKET PERCENTAGE BY PRODUCT TYPE .....	142
TABLE 44 U.S. MARKET PERCENT FOR CENTRAL NERVOUS SYSTEM PSYCHOTHERAPEUTIC DRUGS BY CATEGORY, THROUGH 2007.....	143
TOTAL COMPETITIVE STRUCTURE AND MARKET SHARE .....	143
TABLE 45 TOTAL CENTRAL NERVOUS SYSTEM PSYCHOTHERAPEUTIC DRUG COMEPTITIVE MARKET, 2002.....	144
FIGURE 31 TOTAL CENTRAL NERVOUS SYSTEM PSYCHOTHERAPEUTIC DRUG COMEPTITIVE MARKET, 2002 (%).....	144
INDUSTRY PARTICIPANTS BY PRODUCT TYPE.....	145
TABLE 46 CENTRAL NERVOUS SYSTEM PSYCHOTHERAPEUTIC DRUG MANUFACTURERS BY PRODUCT TYPE, 2002 .....	145
TABLE 46 (CONTINUED) .....	146



COMPETITIVE STRATEGIES BASED ON PRODUCTS .....	146
COMPANY PROFILES .....	147
ABBOTT LABORATORIES .....	147
ASTRAZENECA PLC.....	147
BRISTOL-MYERS SQUIBB COMPANY .....	148
ELI LILLY & COMPANY .....	149
FOREST LABORATORIES, INC. ....	149
GLAXOSMITHKLINE PLC.....	150
F. HOFFMANN-LA ROCHE LTD.....	150
JOHNSON & JOHNSON.....	151
NOVARTIS INTERNATIONAL AG.....	151
ORGANON INTERNATIONAL, INC.....	152
PFIZER, INC. ....	152
PHARMACIA CORP. ....	153
SANOFI-SYNTHELABO .....	153
SHIRE PHARMACEUTICALS GROUP PLC.....	154
WYETH.....	154
Wyeth (Continued).....	155
APPENDIX .....	156
LIST OF COMPANIES .....	156
LIST OF COMPANIES (CONTINUED) .....	157
LIST OF COMPANIES (CONTINUED) .....	158
LIST OF COMPANIES (CONTINUED) .....	159
LIST OF COMPANIES (CONTINUED) .....	160
LIST OF COMPANIES (CONTINUED) .....	161
LIST OF COMPANIES (CONTINUED) .....	162
LIST OF COMPANIES (CONTINUED) .....	163
LIST OF COMPANIES (CONTINUED) .....	164